Source: globenewswire.com
Sanofi (NYSE: SNY) reported that its Q3 2018 financial results on October 31. Net sales for the quarter grew 3.7% to €9.39 billion from €9.06 billion corresponding period previous year. Sanofi Genzyme sales surged 36.1% driven by Immunology and Rare Blood Disorder franchises. Solid growth was experienced from vaccines, with sales up 8.2%, supported by the Pentaxim recovery. Consumer Health Care (CHC) sales increased 4.1% with growth across all geographies and key categories. Diabetes and Cardiovascular sales were down 12.1%. Business net income for the quarter was €2.30 billion or €1.84 per share, up from €2.14 billion or €1.70 per share in the year-ago period. Net income attributable to equity holders of the company rose 45.7% to €2.27 billion from €1.56 billion in the corresponding period previous year. IFRS earnings per share increased to €1.82 from €1.24 last year.
